CAR T-cell treatments, which are specifically designed to target cancer cells, has heralded a new era in the treatment of human cancers, particularly hematologic malignancies. But all too frequently, they exhibit a disconcerting characteristic derived from the immune system's own cells: a sh
Researchers at the Perelman School of Medicine at the University of Pennsylvania have been working on a preclinical study that focuses on a novel strategy that uses a "one-two punch" to assist T cells in attacking solid tumours. The results, which were reported in the Proceedings of the Nati
Researchers from Weill Cornell Medicine, Johns Hopkins University School of Medicine, and Columbia University Irving Medical Center have shown that pregnant women with anxiety have an immune system that differs biologically from pregnant women without anxiety.
Experiments on mice and human cells reveal that the number of specialised immune cells ready to combat skin cancer increased when a novel therapy prevented their egress from melanoma tumours.
PCB2DG, an anti-inflammatory polyphenol, inhibits glutamine absorption by targeting and directly interacting with the main glutamine transporter protein, alanine serine cysteine transporter 2 (ASCT2). This reduction in intracellular glutamine accumulation in CD4+ T cells also inhibits the pr
A new study led by Bruno Silva Santos, group leader and vice-director at the Instituto de Medicina Molecular Joo Lobo Antunes (iMM; Portugal), and published in the scientific journal Cell Reports discovered that T cells influence the transfer of maternal microbiota during birth and nursing,
CAR T-cell therapy, a sort of cancer treatment in which the immune system's T cells are trained to attack tumour cells, was found to be effective in mice with ovarian cancer, according to a study.
According to a study, CAR T-cell therapy, a type of cancer treatment in which the immune system's T cells are trained to attack tumour cells, is successful in mice with ovarian cancer.
Some cancers respond well to immunotherapy, a medication therapy that prompts the immune system to target tumours, although results against lung cancer have been conflicting.
When HIV patients get antiviral medication (ART), their viral levels are reduced to the point that a conventional blood test cannot detect the virus. However, once ART is discontinued, detectable HIV resurfaces, infecting new cells. The cells that release the virus to re-ignite the infection
A new study by researchers at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James) suggests a way to re-energize critical killer immune cells that have become exhausted when fighting cancer or chro